만성 가려움의 병태생리와 감별 진단 및 치료
Pathophysiology, diagnosis, and management of chronic pruritus
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
“Itch” is an unpleasant sensation that elicits a desire to scratch. It is a common complaint among many patients and is associated with a markedly reduced quality of life. The pathogenesis of itch begins with various pruritogens stimulating free nerve endings in the skin, which causes an itch signal to travel through the spinothalamic tract to the brain where the sensation is processed. Scratching an itch initially activates the reward systems in the midbrain and striatum, and this positive reinforcement leads to the repetitive scratching behavior that damages the skin barrier. Mediators such as histamine, serotonin and cytokines are released from the damaged skin, which further aggravates the itch and initiates a vicious “itch-scratch cycle.” Such processes may eventually lead to neural sensitization, where weaker stimuli can cause a more severe pruritic sensation. Chronic itch is one that lasts beyond 6 weeks. Pathologic pruritus can be classified into four different categories based on its cause: dermatologic, systemic, neuropathic, and psychogenic itch. Regardless of the cause, antihistamines are often prescribed as a first-line treatment of chronic itch, but more often than not they prove to be ineffective in bringing symptom relief. Both topical and systemic therapies are used to treat itch, and adequate treatment selection is considered according to symptom severity and chronicity. As the pathogenesis of itch becomes elucidated, more exciting new therapeutic options targeting pruritogenic mediators are becoming increasingly available. This review provides an overview of the pathophysiology, causes and the treatment of chronic itch.
Abstract
“Itch” is an unpleasant sensation that elicits a desire to scratch. It is a common complaint among many patients and is associated with a markedly reduced quality of life. The pathogenesis of itch begins with various pruritogens stimulating free nerve endings in the skin, which causes an itch signal to travel through the spinothalamic tract to the brain where the sensation is processed. Scratching an itch initially activates the reward systems in the midbrain and striatum, and this positive reinforcement leads to the repetitive scratching behavior that damages the skin barrier. Mediators such as histamine, serotonin and cytokines are released from the damaged skin, which further aggravates the itch and initiates a vicious “itch-scratch cycle.” Such processes may eventually lead to neural sensitization, where weaker stimuli can cause a more severe pruritic sensation. Chronic itch is one that lasts beyond 6 weeks. Pathologic pruritus can be classified into four different categories based on its cause: dermatologic, systemic, neuropathic, and psychogenic itch. Regardless of the cause, antihistamines are often prescribed as a first-line treatment of chronic itch, but more often than not they prove to be ineffective in bringing symptom relief. Both topical and systemic therapies are used to treat itch, and adequate treatment selection is considered according to symptom severity and chronicity. As the pathogenesis of itch becomes elucidated, more exciting new therapeutic options targeting pruritogenic mediators are becoming increasingly available. This review provides an overview of the pathophysiology, causes and the treatment of chronic itch.
참고문헌 (60)
- Han L, "Itch mechanisms and circuits", Annu Rev Biophys, 43, pp.331~355 (2014)
- Kye YC, "Textbook of dermatology" (2015), Korea Medbook
- Ständer S, "Prevalence of chronic pruritus in Germany : results of a cross-sectional study in a sample working population of 11, 730", Dermatology, 221, pp.229~235 (2010)
- Ackerley R, "Microneurography as a tool to study the funcTable tion of individual C-fiber afferents in humans : responses from nociceptors, thermoreceptors, and mechanoreceptors", J Neurophysiol, 120, pp.2834~2846 (2018)
- Thangam EB, "The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation : the hunt for new therapeutic targets", Front Immunol, 9, pp.1873~ (2018)
- Dong X, "Peripheral and central mechanisms of itch", Neuron, 98, pp.482~494 (2018)
- Yosipovitch G, "Itch : from mechanism to(novel)therapeutic approaches", J Allergy Clin Immunol, 142, pp.1375~1390 (2018)
- Davidson S, "The multiple pathways for itch and their interactions with pain", Trends Neurosci, 33, pp.550~558 (2010)
- Brennan FP, "Chronic pruritus: histamine is not always the answer!", J Pain Symptom Manage, 50, pp.566~570 (2015)
- Sidbury R, "Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents", J Am Acad Dermatol, 71, pp.327~349 (2014)
- Trier AM, "Cytokine modulation of atopic itch", Curr Opin Immunol, 54, pp.7~12 (2018)
- Reddy VB, "Mas-related G-protein coupled receptors and cowhage-induced itch", J Invest Dermatol, 138, pp.461~464 (2018)
- Melo H, "Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation", Sci Rep, 8, pp.15551~ (2018)
- Phan NQ, "Systemic kappa opioid receptor agonists in the treatment of chronic pruritus : a literature review", Acta Derm Venereol, 92, pp.555~560 (2012)
- Nguyen J, "Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer", Br J Anaesth, 113(Suppl 1), pp.i4~i13 (2014)
- Akira S, "Pathogen recognition and innate immunity", Cell, 124, pp.783~801 (2006)
- Yosipovitch G, "Clinical practice", N Engl J Med, 368, pp.1625~1634 (2013)
- Kang S, "Fitzpatrick's dermatology" (2019), McGraw Hill Education
- Johnston G, "Scabies : diagnosis and treatment", BMJ, 331, pp.619~622 (2005)
- Antia C, "Urticaria : a comprehensive review : epidemiology, diagnosis, and work-up", J Am Acad Dermatol, 79, pp.599~614 (2018)
- Deza G, "Itch in urticaria management", Curr Probl Dermatol, 50, pp.77~85 (2016)
- Antia C, "Urticaria : a comprehensive review : treatment of chronic urticaria, special populations, and disease outcomes", J Am Acad Dermatol, 79, pp.617~633 (2018)
- Brites GS, "Allergic contact dermatitis : from pathophysiology to development of new preventive strategies", Pharmacol Res, 162, pp.105282~ (2020)
- Komiya E, "Molecular and cellular mechanisms of itch in psoriasis", Int J Mol Sci, 21, pp.8406~ (2020)
- Barrea L, "Vitamin D and its role in psoriasis : an overview of the dermatologist and nutritionist", Rev Endocr Metab Disord, 18, pp.195~205 (2017)
- Combs SA, "Pruritus in kidney disease", Semin Nephrol, 35, pp.383~391 (2015)
- Sukul N, "Pruritus and patient reported outcomes in non-dialysis CKD", Clin J Am Soc Nephrol, 14, pp.673~681 (2019)
- Fishbane S, "A phase 3 trial of difelikefalin in hemodialysis patients with pruritus", N Engl J Med, 382, pp.222~232 (2020)
- Wang H, "New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma", Int J Dermatol, 49, pp.1~11 (2010)
- Krajnik M, "Understanding pruritus in systemic disease", J Pain Symptom Manage, 21, pp.151~168 (2001)
- Tan C, "Generalised pruritus as a presentation of Grave’s disease", Malays Fam Physician, 8, pp.20~23 (2013)
- Jackson N, "Skin mast cells in polycythaemia vera : relationship to the pathogenesis and treatment of pruritus", Br J Dermatol, 116, pp.21~29 (1987)
- Saini KS, "Polycythemia vera-associated pruritus and its management", Eur J Clin Invest, 40, pp.828~834 (2010)
- Lelonek E, "Aquagenic pruritus in polycythemia vera : clinical characteristics", Acta Derm Venereol, 98, pp.496~500 (2018)
- Ständer S, "Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine : results of an open-labelled, two-arm proof-of-concept study", Acta Derm Venereol, 89, pp.45~51 (2009)
- Yosipovitch G, "Chronic pruritus : a paraneoplastic sign", Dermatol Ther, 23, pp.590~596 (2010)
- Tarikci N, "Pruritus in systemic diseases : a review of etiological factors and new treatment modalities", ScientificWorldJournal, 2015, pp.803752~ (2015)
- Shapiro RS, "Pruritus as a presenting sign of acquired immunodeficiency syndrome", J Am Acad Dermatol, 16(5 Pt 2), pp.1115~1117 (1987)
- Stern RS, "Clinical practice. Exanthematous drug eruptions", N Engl J Med, 366, pp.2492~2501 (2012)
- Ebata T, "Drug-Induced Itch Management", Curr Probl Dermatol, 50, pp.155~163 (2016)
- Creswell C, "Clinical dermatology" (2013), McGraw-Hill Education
- Reich A, "Drug-induced pruritus : a review", Acta Derm Venereol, 89, pp.236~244 (2009)
- Ganesh A, "Pathophysiology and management of opioid-induced pruritus", Drugs, 67, pp.2323~2333 (2007)
- Ajayi AAL, "Itching, chloroquine, and malaria : a review of recent molecular and neuroscience advances and their contribution to mechanistic understanding and therapeutics of chronic non-histaminergic pruritus", Int J Dermatol, 58, pp.880~891 (2019)
- Ständer S, "Trial of nemolizumab in moderate-to-severe prurigo nodularis", N Engl J Med, 382, pp.706~716 (2020)
- Robbins BA, "Brachioradial pruritus" (2021), StatPearls Publishing
- Oaklander AL, "Mechanisms of pain and itch caused by herpes zoster (shingles)", J Pain, 9(1 Suppl 1), pp.S10~S18 (2008)
- Shimada N, "Pregabalin for postherpetic itch : a case report", JA Clin Rep, 6, pp.24~ (2020)
- Misery L, "Psychogenic itch", Transl Psychiatry, 8, pp.52~ (2018)
- Gabros S, "Topical corticosteroids" (2021), StatPearls Publishing
- Singh R, "Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis", Immunotargets Ther, 9, pp.255~272 (2020)
- Gazerani P, "Antipruritic effects of botulinum neurotoxins", Toxins(Basel), 10, pp.143~ (2018)
- Morgan M, "Therapeutic alternatives for chronic urticaria : an evidence-based review, part 1", Ann Allergy Asthma Immunol, 100, pp.403~411 (2008)[DOI]
- Barniol C, "Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria : a randomized double-blind clinical trial", Ann Emerg Med, 71, pp.125~131 (2018)
- Yasir M, "Corticosteroid adverse effects" (2021), StatPearls Publishing
- Stull C, "Advances in therapeutic strategies for the treatment of pruritus", Expert Opin Pharmacother, 17, pp.671~687 (2016)
- Gokustun D, "25-Hydroxy vitamin D deficiency may be the secret actor in the pathogenesis of uremic pruritus in hemodialysis patients", J Clin Nephrol Res, 3, pp.1053~ (2016)
- Stanescu AMA, "Oral vitamin D therapy in patients with psoriasis", Nutrients, 13, pp.163~ (2021)
- Rorie A, "Beneficial role for supplemental vitamin D3 treatment in chronic urticaria : a randomized study", Ann Allergy Asthma Immunol, 112, pp.376~382 (2014)
- Boyman O, "Adverse reactions to biologic agents and their medical management", Nat Rev Rheumatol, 10, pp.612~627 (2014)